Abstract
Dupilumab blocks the shared receptor component for IL-4/IL-13, key and central drivers of type 2 (T2) inflammation in multiple diseases. In phase 3 QUEST (NCT02414854), add-on dupilumab 200/300mg every 2 weeks, vs placebo, significantly reduced severe exacerbations, improved pre-bronchodilator FEV1, and was generally well tolerated in patients with uncontrolled, moderate-to-severe asthma. Treatment effects were greater in patients with elevated baseline T2 biomarkers (blood eosinophils ≥150cells/μL or FeNO ≥25ppb). This post hoc analysis assessed dupilumab efficacy in patients with T2 asthma on high-dose inhaled corticosteroids (ICS) with/without an allergic phenotype.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
